Clinical Chemistry
Clinical Chemistry
BEER’S LAW
CLEANING OF GLASSWARES
PHOTOMETRY
Principle:
Abs = conc
VARIATIONS OF PHOTOMETRY
0.25 ÷ 0.50 = 𝑋 ÷ 100
Fluorometry
𝑋 = 0.25 ÷ 0.50 𝑥 100
Things to remember about fluorometry:
𝑋 = 0.5 𝑥 100
1. 2 monochromators
𝑋 = 50𝑚𝑔/𝑑𝐿 2. Set at right angle (90 degrees)
3. UV light
4. More sensitive/specific
COMPONENTS OF SPECTROPHOTOMETER
𝑁 = 𝑀 × 𝑛𝑜. 𝑜𝑓 ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛
𝑁 =4 ×1
𝑁 = 4𝑁
MUST KNOW
• Except somatostatin and insulin, which does not
• Glycol aldehyde – simplest carbohydrate (CHO) increase blood glucose instead they decrease
• Glucose, maltose, fructose, lactose and blood glucose.
galactose – reducing substances/sugars • Somatostatin – inhibit insulin and glucagon
SPECIMEN CONSIDERATIONS AND PREPARATIONS NEOCUPREINE METHOD
• Whole blood, plasma, serum, CSF, urine, serous 𝐶𝑢1+ + 𝑁𝑒𝑜𝑐𝑢𝑝𝑟𝑒𝑖𝑛𝑒 → 𝑦𝑒𝑙𝑙𝑜𝑤 − 𝑦𝑒𝑙𝑙𝑜𝑤 𝑜𝑟𝑎𝑛𝑔𝑒
fluid, synovial fluid can be used as sample.
• Standard clinical specimen in hospital is serum
but in board exam it is fasting venous plasma BENEDICT’S METHOD
• Fasting blood sugar should be obtained after 10
• For reducing sugars
– 12 hours of fasting.
• Fasting for lipids is 12-14 hours 𝑔𝑙𝑢𝑐𝑜𝑠𝑒
𝐶𝑢𝑆𝑂4
• Fasting blood glucose with lipid is 10-12 hours 𝑅𝑒𝑑𝑢𝑐𝑖𝑛𝑔 𝑠𝑢𝑔𝑎𝑟𝑠
• Whole blood gives 10-15% lower than the → 𝑔𝑟𝑒𝑒𝑛, 𝑦𝑒𝑙𝑙𝑜𝑤, 𝑜𝑟𝑎𝑛𝑔𝑒, 𝑏𝑟𝑖𝑐𝑘 𝑟𝑒𝑑 𝑝𝑟𝑒𝑐𝑖𝑝𝑖𝑡𝑎𝑡𝑒
glucose levels than serum or plasma.
• Serum is appropriate for glucose analysis if it is
separated from the cells within 30-60 minutes.
• Glucose is metabolized at room temperature at Chemical methods:
a rate of 7mg/dL/hr.
• At 4 degree Celsius, glucose decreases by • Ferric reduction
approximately 2mg/dL/hr • Condensation method
• 2mg of sodium fluoride per mL of whole blood
prevents glycolysis for up o 48 hours (2 days).
• Fluoride binds magnesium which causes FERRIC REDUCTION
inhibition of the enzyme enolase. 𝑔𝑙𝑢𝑐𝑜𝑠𝑒
• CSF glucose concentration is approximately 60 - 𝐹𝑒 3+ → 𝐹𝑒 2+
𝑅𝑒𝑑𝑢𝑐𝑖𝑛𝑔 𝑠𝑢𝑔𝑎𝑟𝑠
70% that of plasma concentration.
• CSF glucose should be obtained 1-2 hours
before spinal tap. CONDENSATION METHOD
∆100𝐶
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 𝑂𝑟𝑡ℎ𝑜𝑡𝑜𝑙𝑜𝑢𝑖𝑑𝑖𝑛𝑒 𝑚𝑒𝑡ℎ𝑜𝑑
METHODOLOGIES FOR GLUCOSE ASSAY 𝐻𝐴𝐶
→ 𝑏𝑙𝑢𝑖𝑠ℎ 𝑔𝑟𝑒𝑒𝑛 𝑐𝑜𝑙𝑜𝑟
Chemical Methods
Copper reduction:
Enzymatic Methods:
• Folin Wu method
• Nelson Somoygi • Glucose oxidase
• Neocupreine method o Polarographic
o Colorimetric
• Hexokinase G6PD – oldest; reference method;
FOLIN WU MTEHOD sensitive and specific
𝑔𝑙𝑢𝑐𝑜𝑠𝑒
𝐶𝑢2+ → 𝐶𝑢1+
𝑅𝑒𝑑𝑢𝑐𝑖𝑛𝑔 𝑠𝑢𝑔𝑎𝑟𝑠
GLUCOSE OXIDASE
𝐶𝑢1+ + 𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑚𝑜𝑙𝑦𝑏𝑑𝑎𝑡𝑒 → 𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑚𝑜𝑙𝑦𝑏𝑑𝑒𝑛𝑢𝑚 𝑏𝑙𝑢𝑒
𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑜𝑥𝑖𝑑𝑎𝑠𝑒
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 𝑂𝑥𝑦𝑔𝑒𝑛
→ 𝑔𝑙𝑢𝑐𝑜𝑛𝑖𝑐 𝑎𝑐𝑖𝑑 + ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛 𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑒
• Polarographic
NELSON SOMOYGI • Colorimetric
𝐶𝑢1+ + 𝑎𝑟𝑠𝑒𝑛𝑜𝑚𝑜𝑙𝑦𝑏𝑑𝑎𝑡𝑒 → 𝑎𝑟𝑠𝑒𝑛𝑜𝑚𝑜𝑙𝑦𝑏𝑑𝑒𝑛𝑢𝑚 𝑏𝑙𝑢𝑒
𝐻𝑦𝑑𝑟𝑜𝑔𝑒𝑛 𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑒 + 𝐶ℎ𝑟𝑜𝑚𝑜𝑔𝑒𝑛
𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑎𝑠𝑒 • Cholesterol – serves as part of cell membrane,
as parent chain for cholesterol based hormones
→ 𝑊𝑎𝑡𝑒𝑟
such as aldosterone, cortisol and sex hormones.
+ 𝑂𝑥𝑖𝑑𝑖𝑧𝑒𝑑 𝐶ℎ𝑟𝑜𝑚𝑜𝑔𝑒𝑛
o Exists in the body in two different
forms:
o Cholesterol esters – accounts to
HEXOKINASE-G6PD
approximately 70% of total cholesterol
𝐻𝑒𝑥𝑜𝑘𝑖𝑛𝑎𝑠𝑒 of the body, composed of a cholesterol
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 𝐴𝑇𝑃 → 𝐺6𝑃𝐷 + 𝐴𝐷𝑃
ring with a fatty acid.
𝐺6𝑃𝐷 o Free cholesterol – accounts to
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 𝑁𝐴𝐷𝑃 approximately 30% of total cholesterol;
→ 6 𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑔𝑙𝑢𝑐𝑜𝑛𝑎𝑡𝑒 + 𝑁𝐴𝐷𝑃𝐻 also known as unesterified cholesterol.
• Apolipoproteins
LIPIDS
Functions Major
Functions: Source
Apo A1 Major structural protein in Liver
• Storage HDL. Activates LCAT; ligand and
• Cushion for HDL binding intestine
• Integral part of phospholipid Apo A-II Structural protein in HDL; Liver
• Hormone synthesis activates LCAT. Enhances
hepatic triglyceride lipase
activity.
FORMS OF LIPIDS Apo A-IV Component of intestinal Intestine
lipoproteins
• Triglyceride Apo B-48 Primarily structural protein Intestine
o Possess 3 molecules of fatty acids and a in chylomicrons
molecule of glycerol which serves as the Apo B-100 Major structural protein in Liver
backbone. VLDL and LDL. Ligand for
o Serves as the main storage of lipid in the LDL receptor.
man, as insulator or shock absorber, Apo C-I Activates lipoprotein lipase. Liver
Apo C-II Activates lipoprotein lipase; Liver
and as an integral part of the cell
activates LCAT.
membrane.
Apo C-III Inhibits lipoprotein lipase. Liver Step 3:
Inhibits receptor
recognition of Apo E. • Reagent: sodium periodate
Apo E2, 3, Binds to LDL-receptor and Liver • Purpose: converts glycerol to formaldehyde
4 remnant receptor.
Step 4:
Apo (a) Structural protein for Lp (a). Liver
May inhibit plasminogen • Reagent: chromotropic acid dissolve in H2SO4
binding. • Purpose: Color reaction
Lp(a) – abnormal lipoprotein seen in patients with CHD
and AMI.
SPECIMEN CONSIDERATIONS AND PATIENT
PREPARATION
CHEMICAL COMPOSITION OF DIFFERENT LIPOPROTEIN
CLASSES: • Fasting requirement at least 12 hours
• No to hemolyzed sample.
Prot Cholest Cholest Triglycer Phospho • Avoid water contamination
ein erol eryl ides lipid
• Serum or EDTA-plasma may be used
esters
CM 1-2 1-3 2-4 80-95 3-6 • No to icteric specimens.
VL 6-10 4-8 16-22 45-65 15-20 • Serum is preferred; 24 hour urine and serous
DL fluids can also be used.
IDL Intermediate between VLDL and LDL
LD 18- 6-8 45-50 4-8 28-24
ELECTROPHORESIS
L 22
HD 45- 3-5 15-20 2-7 26-32 • Regions are stained using ponceau s, coomasie
L 55 brilliant blue, amido black
• Electrophoretic patterns:
SEPARATING LIPOPROTEINS o Beta-gamma bridging – seen in patients
with liver cirrhosis.
• Electrophoresis o Bence jones protein – seen in cases of
• Ultracentrifugation monoclonal gammopathy.
o Increase a2-macroglobulin, decrease
albumin – seen in patients with
ABNORMAL LIPOPROTEINS nephrotic syndrome.
o Decrease a1 antitrypsin – seen in
• Beta-VLDL patients with emphysema
• Lp(a)